Related Experiment Videos
[Angioimmunoblastic lymphadenopathy. Evolution into malignant lymphoma (author's transl)]
Zentralblatt Fur Allgemeine Pathologie U. Pathologische Anatomie
|January 1, 1980
Summary
Angioimmunoblastic lymphadenopathy (AIL) can progress into malignant lymphoma, a rare but serious complication. This case highlights the importance of monitoring AIL for signs of malignancy, as early detection is crucial for patient outcomes.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Angioimmunoblastic lymphadenopathy (AIL) was historically considered a benign reactive lymph node condition.
- Recent literature indicates an increasing number of AIL cases progressing to malignant lymphomas.
Observation:
- A 74-year-old female initially diagnosed with lymphogranulomatosis X presented with evolving criteria for malignancy within four weeks.
- Despite initial diagnosis, the patient's condition rapidly deteriorated, leading to death seven months after disease onset.
Findings:
- Comprehensive histological, cytochemical, cytophotometrical, electron microscopical, and immunological analyses were performed.
- The case demonstrates a clear progression from an initial diagnosis to evident malignancy.
Implications:
- The findings underscore that angioimmunoblastic lymphadenopathy (AIL) carries a significant risk of evolving into malignant lymphoma.
- Variable differentiation of lymphomas arising from AIL should be anticipated, necessitating vigilant follow-up and advanced diagnostic techniques.